The RvT4 molecule strengthens the body’s natural defenses against atherosclerosis in patients with rheumatoid arthritis. This has been shown by a study published in the journal. Nature Communication.
Rheumatoid arthritis affects about 1% of people. In addition to arthritis, the disease is associated with a doubled risk of atherosclerosis, which is the blockage of arteries by fatty plaques. Atherosclerosis increases the risk of stroke or heart attack.
Previously, scientists discovered that in rheumatoid arthritis, the level of the RvT4 molecule is noticeably reduced, and the stronger it is, the higher the degree of atherosclerosis. The new study shows that treating mice with arthritis with an RvT4-based drug reduced inflammation in blood vessels.
This occurs due to the reprogramming of macrophages, a group of leukocytes that accumulate in diseased vessels. Researchers noticed that fats prevented macrophages from doing their normal job of destroying unwanted cells and reducing local inflammation. RvT4 protected macrophages from the influence of fats and made them more effective in fighting atherosclerosis.
The research may help develop new treatments for atherosclerosis in people with rheumatoid arthritis.
Previous scientists named Gastrointestinal disease that may increase the risk of rheumatoid arthritis.